^
Association details:
| Biomarker: | EGFR L861Q |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC
Excerpt:
...in the present study, the KYSE270 cell line with an EGFR L861Q mutation was hypersensitive to afatinib….This cell line, however, was not sensitive to erlotinib, a reversible EGFR inhibitor.
DOI:
10.1158/1535-7163.MCT-15-0737
